Published in J Clin Psychopharmacol on June 01, 2007
Duloxetine treatment of social anxiety disorder with comorbid major depression. J Clin Psychopharmacol (2008) 0.76
The role of duloxetine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat (2008) 0.75
[Brain effects of cannabis--neuroimaging findings]. Rev Bras Psiquiatr (2005) 2.05
Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.55
Cavum septum pellucidum and adhesio interthalamica in schizophrenia: an MRI study. Eur Psychiatry (2006) 1.54
Psychometric properties of the Fagerström Test for Nicotine Dependence. J Bras Pneumol (2009) 1.46
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology (2011) 1.41
Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol (2009) 1.40
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol (2010) 1.31
Comparability between telephone and face-to-face structured clinical interview for DSM-IV in assessing social anxiety disorder. Perspect Psychiatr Care (2008) 1.21
Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology (2004) 1.10
[Factorial structure of the Brazilian version of the Modified Reasons for Smoking Scale]. Rev Assoc Med Bras (2009) 1.08
Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol (2006) 1.08
Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry (2012) 1.07
Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf (2011) 1.03
Altered gray matter morphometry and resting-state functional and structural connectivity in social anxiety disorder. Brain Res (2011) 1.03
Adhesio interthalamica alterations in schizophrenia spectrum disorders: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry (2011) 1.03
The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr (2009) 1.02
[Therapeutical use of the cannabinoids in psychiatry]. Rev Bras Psiquiatr (2010) 0.98
Are cavum septum pellucidum abnormalities more common in schizophrenia spectrum disorders? A systematic review and meta-analysis. Schizophr Res (2010) 0.94
Structural magnetic resonance imaging in anxiety disorders: an update of research findings. Rev Bras Psiquiatr (2008) 0.92
National Science and Technology Institute for Translational Medicine (INCT-TM): advancing the field of translational medicine and mental health. Rev Bras Psiquiatr (2010) 0.91
Interaction between cannabidiol (CBD) and ∆(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology (Berl) (2011) 0.90
Clozapine monotherapy for catatonic schizophrenia: should clozapine be the treatment of choice, with catatonia rather than psychosis as the main therapeutic index? J Psychopharmacol (2005) 0.90
Psychometric qualities of the Brazilian versions of the Fagerström Test for Nicotine Dependence and the Heaviness of Smoking Index. Nicotine Tob Res (2009) 0.90
Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behav Brain Res (2010) 0.89
Neuroimaging in specific phobia disorder: a systematic review of the literature. Rev Bras Psiquiatr (2012) 0.89
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev Bras Psiquiatr (2012) 0.89
Social anxiety disorder women easily recognize fearfull, sad and happy faces: the influence of gender. J Psychiatr Res (2009) 0.89
Evaluation of the psychometric properties of the Social Phobia Inventory in university students. Compr Psychiatry (2010) 0.88
Social phobia in Brazilian university students: prevalence, under-recognition and academic impairment in women. J Affect Disord (2011) 0.86
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study. J Clin Psychopharmacol (2016) 0.86
The accuracy of diagnosis of major depression in patients with Parkinson's disease: a comparative study among the UPDRS, the geriatric depression scale and the Beck depression inventory. Arq Neuropsiquiatr (2008) 0.85
Oxytocin interference in the effects induced by inhalation of 7.5% CO(2) in healthy volunteers. Hum Psychopharmacol (2012) 0.84
Further study of the psychometric qualities of a brief screening tool for social phobia (MINI-SPIN) applied to clinical and nonclinical samples. Perspect Psychiatr Care (2010) 0.83
Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Curr Pharm Des (2012) 0.83
[Guidelines of the Brazilian Medical Association for the diagnosis and differential diagnosis of social anxiety disorder]. Rev Bras Psiquiatr (2010) 0.83
Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats. Psychopharmacology (Berl) (2012) 0.83
Are there differences between early- and late-onset social anxiety disorder? Rev Bras Psiquiatr (2007) 0.82
Cross- cultural validation of the Brazilian Portuguese version of the Social Phobia Inventory (SPIN): study of the items and internal consistency. Rev Bras Psiquiatr (2008) 0.82
Further psychometric study of the Beck Anxiety Inventory including factorial analysis and social anxiety disorder screening. Int J Psychiatry Clin Pract (2011) 0.82
(1)H magnetic resonance spectroscopy imaging of the hippocampus in patients with panic disorder. Psychiatry Res (2010) 0.82
Electroconvulsive therapy for coexistent schizophrenia and obsessive-compulsive disorder. J Clin Psychiatry (2005) 0.82
Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis. Eur J Pharmacol (2012) 0.82
The fast alcohol screening test (FAST) is as good as the AUDIT to screen alcohol use disorders. Subst Use Misuse (2010) 0.81
Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Rev Bras Psiquiatr (2010) 0.80
Anxiety and joint hypermobility association: a systematic review. Rev Bras Psiquiatr (2012) 0.80
Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm. Neuropsychopharmacology (2011) 0.79
COOP/WONCA charts as a screen for mental disorders in primary care. Ann Fam Med (2011) 0.79
Short admission in an emergency psychiatry unit can prevent prolonged lengths of stay in a psychiatric institution. Rev Bras Psiquiatr (2009) 0.79
Psychometrics properties of early trauma inventory self report - short form (ETISR-SR) for the Brazilian context. PLoS One (2013) 0.79
Cannabidiol Exposure During Neuronal Differentiation Sensitizes Cells Against Redox-Active Neurotoxins. Mol Neurobiol (2014) 0.79
Agomelatine in the treatment of social anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.79
Total agenesis of the corpus callosum in a patient with childhood-onset schizophrenia. Arq Neuropsiquiatr (2007) 0.78
Disability profile/clinician-rated: validity for Brazilian university students with social anxiety disorder. Span J Psychol (2013) 0.78
A motivational profile for smoking among adolescents. J Addict Med (2013) 0.78
Why should Cannabis be Considered Doping in Sports? Front Psychiatry (2013) 0.78
[Cannabis sativa: the plant that can induce unwanted effects and also treat them]. Rev Bras Psiquiatr (2010) 0.78
Social anxiety and negative early life events in university students. Rev Bras Psiquiatr (2012) 0.77
Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol (2013) 0.77
Adaptation and initial psychometric study of the self-report version of Liebowitz Social Anxiety Scale (LSAS-SR). Int J Psychiatry Clin Pract (2012) 0.77
Method for evaluating subjective states of awareness that accompany recognition: adaptation for use in Portuguese-speaking patients with schizophrenia. Rev Bras Psiquiatr (2005) 0.77
Electrodermically nonresponsive schizophrenia patients make more errors in the Stroop Color Word Test, indicating selective attention deficit. Schizophr Bull (2002) 0.77
Validity of a Brazilian version of the Zung self-rating depression scale for screening of depression in patients with Parkinson's disease. Parkinsonism Relat Disord (2009) 0.77
Is the Fagerström Test for Nicotine Dependence a good instrument to assess tobacco use in patients with schizophrenia? Rev Bras Psiquiatr (2009) 0.77
Duloxetine in the treatment of panic disorder. Int J Neuropsychopharmacol (2005) 0.77
Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis. CNS Neurol Disord Drug Targets (2015) 0.77
Cannabis use, cognition and brain structure in first-episode psychosis. Schizophr Res (2013) 0.77
Validation and internal consistency of Patient Health Questionnaire-9 for major depression in Parkinson's disease. Age Ageing (2013) 0.76
Does social phobia remain the 'Ugly Duckling' of anxiety disorders? Rev Bras Psiquiatr (2009) 0.76
Proton magnetic resonance spectroscopy of the frontal lobe in schizophrenics: a critical review of the methodology. Rev Hosp Clin Fac Med Sao Paulo (2004) 0.76
Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection. Mol Neurobiol (2013) 0.76
Higher prevalence of major depressive symptoms in Brazilians aged 14 and older. Rev Bras Psiquiatr (2013) 0.76
Is the highest density of CB1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning? Expert Rev Neurother (2011) 0.76
Neuroimaging of depression in Parkinson's disease: a review. Int Psychogeriatr (2013) 0.76
Effects of pregabalin on behavioral alterations induced by ketamine in rats. Rev Bras Psiquiatr (2012) 0.75
Depressive symptoms and alcohol correlates among Brazilians aged 14 years and older: a cross-sectional study. Subst Abuse Treat Prev Policy (2014) 0.75
Brazil launches an innovative program to develop the National Institutes for Science and Technology (INCTs): the INCT for Translational Medicine. Rev Bras Psiquiatr (2009) 0.75
Validation of the state version of the Self-Statement during Public Speaking Scale. Rev Bras Psiquiatr (2013) 0.75
Assessment of referrals to an OT consultation-liaison service: a retrospective and comparative study. Scand J Occup Ther (2010) 0.75
Accuracy of psychiatric diagnosis performed under indirect supervision. Rev Bras Psiquiatr (2005) 0.75
Trismus induced by fluoxetine. J Clin Psychopharmacol (2009) 0.75
On museums and scientific journals. Rev Bras Psiquiatr (2012) 0.75
New trends in anxiety disorders. Rev Bras Psiquiatr (2012) 0.75